← All companies
Arcus Biosciences, Inc.
RCUS - CIK 0001724521
Market cap$2.86 B
Rank#1847
SEC filings567
Arcus Biosciences, Inc. trades as RCUS and has a market capitalization of $2.86 B, making it the #1847 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $33.00M, down 35.3% from the prior year and net income of -$353.00M. This page tracks Arcus Biosciences, Inc. through 567 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$33.00MFY 2025
Net income (latest FY)-$353.00MFY 2025
Operating cash flow (latest FY)-$482.00MFY 2025
Total assets (latest FY)$1.14BFY 2025
Net margin-1069.7%latest FY
Financial performance
Over the last 8 fiscal years Arcus Biosciences, Inc.'s revenue grew from $1.41M to $33.00M, a compound annual growth rate of 48.3%. Net profit margin expanded from -3756.7% to -1069.7% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $2.86 B
- Share price (derived)market cap / shares outstanding
- $22.70
- EPS (diluted)FY 2025
- $-3.29
- Shares outstandingas of 2026-04-30
- 0.13B
- Total equityas of 2026-03-31
- $524.00M
- Return on equity
- -67.4%
- Long-term debtas of 2026-03-31
- $100.00M
- Cash & equivalentsas of 2026-03-31
- $201.00M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Insider sale notice | 144 | 2026-04-23 |
| Annual report to shareholders | ARS | 2026-04-21 |
Recent press releases
- Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthc...2026-05-26
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET.
- Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pi...2026-04-21
_Arcus outlines development strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including the potential to become the first HIF-2a inhibitor-based tyrosine kinase inhibitor (TKI)-free regimen in the first-line (1L) setting_
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financia...2026-02-26
Investors interested in listening to the conference call may do so by dialing +1 (585) 542-9983 (local) or +1 (833) 461-5787 (toll-free), using Meeting ID: 304747896. Participants may also register for the call online using the following link: https://events.q4inc.com/attendee/304747896. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.
- Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Similar companies
The largest companies sharing Arcus Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is Arcus Biosciences, Inc.'s market cap?
Arcus Biosciences, Inc. (RCUS) has a market capitalization of $2.86 B as of 2026-06-10, ranking #1847 among US-listed companies.
How much revenue does Arcus Biosciences, Inc. make?
Arcus Biosciences, Inc. reported revenue of $33.00M for fiscal year 2025, a decrease of 35.3% year over year.
Is Arcus Biosciences, Inc. profitable?
In its latest fiscal year Arcus Biosciences, Inc. reported a net loss of $353.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.